Evogene (TSE:EVGN – Free Report) had its price objective trimmed by Ventum Financial from C$4.00 to C$3.00 in a research note issued to investors on Friday morning,BayStreet.CA reports.
Evogene Stock Performance
About Evogene
Evogene is a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its broadly applicable Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through the power of Big Data and Artificial Intelligence, has been designed to computationally discover and guide the development of life-science products based on microbes, small molecules and genetic elements.
Featured Stories
- Five stocks we like better than Evogene
- 3 REITs to Buy and Hold for the Long Term
- Disney’s Magic Strategy: Reinventing the House of Mouse
- What is a support level?
- Volatility in Semis? 3 Stable Alternatives to NVIDIA and SMCI
- What Are the FAANG Stocks and Are They Good Investments?
- Vertiv’s Cool Tech Makes Its Stock Red-Hot
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.
